BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38731910)

  • 1. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.
    Bhatt DK; Daemen T
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment.
    Chattopadhyay S; Hazra R; Mallick A; Gayen S; Roy S
    Biochim Biophys Acta Rev Cancer; 2024 Jul; 1879(4):189110. PubMed ID: 38754793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic viruses for induction of anti-tumor immunity.
    Tong AW; Senzer N; Cerullo V; Templeton NS; Hemminki A; Nemunaitis J
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1750-60. PubMed ID: 21740355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
    Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
    Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
    Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.
    Workenhe ST; Mossman KL
    Mol Ther; 2014 Feb; 22(2):251-256. PubMed ID: 24048442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy.
    Niemann J; Woller N; Brooks J; Fleischmann-Mundt B; Martin NT; Kloos A; Knocke S; Ernst AM; Manns MP; Kubicka S; Wirth TC; Gerardy-Schahn R; Kühnel F
    Nat Commun; 2019 Jul; 10(1):3236. PubMed ID: 31324774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y; Xie D; Yang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic viruses and immunity.
    Chaurasiya S; Chen NG; Fong Y
    Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
    Alvarez-Breckenridge CA; Choi BD; Suryadevara CM; Chiocca EA
    Curr Opin Virol; 2015 Aug; 13():25-32. PubMed ID: 25846988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virotherapy: Challenges and solutions.
    Goradel NH; Baker AT; Arashkia A; Ebrahimi N; Ghorghanlu S; Negahdari B
    Curr Probl Cancer; 2021 Feb; 45(1):100639. PubMed ID: 32828575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Virotherapy in Glioma Tumors.
    Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers.
    Song XT
    Discov Med; 2013 Dec; 16(90):261-6. PubMed ID: 24333405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.